Literature DB >> 30814058

Tranexamic acid is an active site inhibitor of urokinase plasminogen activator.

Guojie Wu1,2, Blake A Mazzitelli1,2, Adam J Quek1,2, Matthew J Veldman1,2, Paul J Conroy1,2, Tom T Caradoc-Davies1,2,3, Lisa M Ooms1,2, Kellie L Tuck4, Jonathan G Schoenecker5, James C Whisstock1,2,6, Ruby H P Law1,2.   

Abstract

Entities:  

Year:  2019        PMID： 30814058      PMCID： PMC6418500          DOI： 10.1182/bloodadvances.2018025429

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  23 in total

1.  Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.

Authors:  Jonathan J Morrison; Joseph J Dubose; Todd E Rasmussen; Mark J Midwinter
Journal:  Arch Surg       Date:  2011-10-17

Review 2.  New insights into the structure and function of the plasminogen/plasmin system.

Authors:  Ruby H P Law; Diana Abu-Ssaydeh; James C Whisstock
Journal:  Curr Opin Struct Biol       Date:  2013-11-16       Impact factor: 6.809

3.  Development of Shiny app tools to simplify and standardize the analysis of hemostasis assay data: communication from the SSC of the ISTH.

Authors:  C Longstaff
Journal:  J Thromb Haemost       Date:  2017-03-17       Impact factor: 5.824

4.  X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors.

Authors:  Ruby H P Law; Guojie Wu; Eleanor W W Leung; Koushi Hidaka; Adam J Quek; Tom T Caradoc-Davies; Devadharshini Jeevarajah; Paul J Conroy; Nigel M Kirby; Raymond S Norton; Yuko Tsuda; James C Whisstock
Journal:  Blood Adv       Date:  2017-05-09

5.  Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator.

Authors:  M M C G Silva; C Thelwell; S C Williams; C Longstaff
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

6.  The traumatic side of fibrinolysis.

Authors:  Robert L Medcalf
Journal:  Blood       Date:  2015-04-16       Impact factor: 22.113

7.  The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.

Authors:  Ian Roberts; Haleema Shakur; Adefemi Afolabi; Karim Brohi; Tim Coats; Yashbir Dewan; Satoshi Gando; Gordon Guyatt; B J Hunt; Carlos Morales; Pablo Perel; David Prieto-Merino; Tom Woolley
Journal:  Lancet       Date:  2011-03-26       Impact factor: 79.321

8.  Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice.

Authors:  Nuha Hijazi; Rami Abu Fanne; Rinat Abramovitch; Serge Yarovoi; Muhamed Higazi; Suhair Abdeen; Maamon Basheer; Emad Maraga; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Blood       Date:  2015-02-11       Impact factor: 22.113

9.  An in vitro study of the effects of t-PA and tranexamic acid on whole blood coagulation and fibrinolysis.

Authors:  Anne Godier; Kiran Parmar; Karuna Manandhar; Beverley J Hunt
Journal:  J Clin Pathol       Date:  2016-07-21       Impact factor: 3.411

Review 10.  Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Med Res Rev       Date:  2014-03-21       Impact factor: 12.944
View more
  3 in total

Review 1.  Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.

Authors:  Nehad S El Salamouni; Benjamin J Buckley; Marie Ranson; Michael J Kelso; Haibo Yu
Journal:  Biophys Rev       Date:  2022-01-06

Review 2.  Safety and Efficacy of Local Tranexamic Acid for the Prevention of Surgical Bleeding in Soft-Tissue Surgery: A Review of the Literature and Recommendations for Plastic Surgery.

Authors:  Kjersti Ausen; Reidar Fossmark; Olav Spigset; Hilde Pleym
Journal:  Plast Reconstr Surg       Date:  2022-03-01       Impact factor: 4.730

3.  Tranexamic acid-loaded hemostatic nanoclay microsphere frameworks.

Authors:  Isabelle Denry; Jean-Marie Nédélec; Julie A Holloway
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2021-07-21       Impact factor: 3.368
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.